Latest News

Poxel Announces Updates to its Management Team

LYON, France–(BUSINESS WIRE)–POXEL SA (Euronext: POXEL – FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes and non-alcoholic steatohepatitis (NASH), today announced changes in its management team, with the appointment of Quentin Durand as Chief Legal Officer, and the departure of Christophe Arbet-Engels, MD, PhD, MBA, Chief Medical Officer and Executive Vice President (EVP) Late Development & M

Source link

Related posts

Report Warns of Dog Illness That Can Spread to Owners


Principles for public space design, planning to do better


Hep B Core Antibody-Positive Organs May Provide Solutions to the Organ Donor Crisis


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy